Categories AlphaGraphs, Earnings, Health Care
A visual representation of Johnson & Johnson (JNJ) Q1 2020 earnings results
Johnson & Johnson (NYSE: JNJ) reported that its first-quarter 2020 earnings and revenue came in above the analysts’ expectations citing product sales as well as lower costs and expenses. Region-wise, sales were better in the US than international. The Consumer and Pharmaceutical segments experienced solid high-single-digit growths despite declines in the Medical Devices segment.
The company is mobilizing its resources in the fight against the COVID-19 pandemic. The impact of COVID-19 has been included in the guidance. The reported sales outlook for fiscal 2020 was lowered to $77.5-80.5 billion from $85.4-86.2 billion. Adjusted earnings guidance was reduced to $7.50-7.90 from $8.95-9.10.
Past Performance
4Q19 
3Q19 
2Q19
Most Popular
CCL Earnings: Carnival Corp. Q4 2024 revenue rises 10%
Carnival Corporation & plc. (NYSE: CCL) Friday reported strong revenue growth for the fourth quarter of 2024. The cruise line operator reported a profit for Q4, compared to a loss
Key metrics from Nike’s (NKE) Q2 2025 earnings results
NIKE, Inc. (NYSE: NKE) reported total revenues of $12.4 billion for the second quarter of 2025, down 8% on a reported basis and down 9% on a currency-neutral basis. Net
FDX Earnings: FedEx Q2 2025 adjusted profit increases; revenue dips
Cargo giant FedEx Corporation (NYSE: FDX), which completed an organizational restructuring recently, announced financial results for the second quarter of 2025. Second-quarter earnings, excluding one-off items, were $4.05 per share,
Comments